ESA Market Highlights Need For Follow-On Biologic Pathway – MedPAC
Executive Summary
The lack of price competition for erythropoiesis-stimulating agents is one example of the need for a mechanism to approve biologic generics, the Medicare Payment Advisory Committee asserts in its March report to Congress
You may also be interested in...
Potential Federal Drug Savings Could Propel Biosimilars Bill
The potential for biosimilars to lower Medicare and Medicaid drug spending could help catalyze support for a follow-on biologics bill this year, a Capitol Hill staffer predicted at the Food and Drug Law Institute's annual conference March 26
Potential Federal Drug Savings Could Propel Biosimilars Bill
The potential for biosimilars to lower Medicare and Medicaid drug spending could help catalyze support for a follow-on biologics bill this year, a Capitol Hill staffer predicted at the Food and Drug Law Institute's annual conference March 26
Biogenerics Bill From Reps. Eshoo And Barton “Expects” Limits On Substitution
Interchangeability standards that come close to those sought by the Bush administration are contained in follow-on biologics legislation that is expected to be introduced shortly by Rep. Anna Eshoo, D-Calif